Pluri Inc. is a pioneering biotechnology company focused on regenerative medicine and immunotherapy, leveraging its proprietary technology platform to create cutting-edge cell-based therapies targeting oncology and degenerative diseases. Dedicated to addressing significant unmet medical needs, Pluri is expanding its pipeline of innovative therapeutics while forging strategic collaborations that enhance its capability to improve patient outcomes. With its commitment to advancing healthcare solutions, Pluri is poised to emerge as a key player in the biotech sector, driving growth and delivering meaningful advancements in patient care.
| Revenue (TTM) | $1.08M |
| Gross Profit (TTM) | 464,000 |
| EBITDA | $-25.52M |
| Operating Margin | -3914.00% |
| Return on Equity | -1022.00% |
| Return on Assets | -51.20% |
| Revenue/Share (TTM) | $0.12 |
| Book Value | $-1.78 |
| Price-to-Book | 306.56 |
| Price-to-Sales (TTM) | 19.00 |
| EV/Revenue | 43.63 |
| EV/EBITDA | -1.28 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -60.90% |
| Shares Outstanding | $10.79M |
| Float | $4.64M |
| % Insiders | 46.57% |
| % Institutions | 12.55% |
Volatility is currently expanding
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a services-led, product-enabled, AI-native cybersecurity company, is pleased to announce the results of its Annual General Meeting (the "Meeting") of shareholders held on June 16, 2026. All resolutions presented to the shareholders were approved.
Two regenerative aesthetic and longevity products, with clinically validated ingredients , are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. (“Cellav”), has completed the development and U.S. cosmetic product listings of two flagship regenerative aesthetic products - Regenativo+ and Placento+, clearing the path for commercial launch in the United States.
